Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: Relevance of natural killer cells

Clinical and Experimental Immunology

Volumn 151, Issue 2, 2008, Pages 235-243

  Airas, L ^a,b   Saraste, M ^a   Rinta, S ^c   Elovaara, I ^c   Huang, Y H ^d   Wiendl, H ^d   Airas, Laura ^b   Väisänen, Saara ^b   Saraste, Maija ^a   Alanen, Anna ^b   Färkkilä, Markus ^e   Multanen, Juha ^e   Kaaja, Risto ^e   Reunanen, Mauri ^f   Remes, Anne ^f   Raudaskoski, Tytti ^f   Pirttilä, Tuula ^g   Räsänen, Maritta ^g   Elovaara, Irina ^h   Uotila, Jukka ^h   Kuoppamäki, Mikko ⁱ   Närhinen, Laila ⁱ   Baumann, Peter ^j   Aliharmi, Riitta ^j   Tuisku, Seppo ^k   Huhtakangas, Juha ^l   Salmivaara, Annikki ^m   Kupila, Laura ⁿ   Kaislakoski, Merja ^o   Sarasoja, Taneli ^p   more..

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY OF OULU   (Finland)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

^h TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

ⁱ SATAKUNTA CENTRAL HOSPITAL   (Finland)

^j Rovaniemi Central Hospital

^k Keski Pohjanmaan Erikoissairaanhoito Ja Peruspalvelukuntayhtyma   (Finland)

^l KAINUU CENTRAL HOSPITAL   (Finland)

^m PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

ⁿ Rauma District Hospital

^o Joensuu Central Hospital   (Finland)

^p JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

more..

Author keywords

Autoimmunity; Immunoregulation; Multiple sclerosis; NK cell; Pregnancy

Indexed keywords

BETA1A INTERFERON; CD19 ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GLATIRAMER; INTERFERON BETA SERINE; REBIF 22; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DOWN REGULATION; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INTERFERON PRODUCTION; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PREGNANCY; PRIORITY JOURNAL; RECURRENCE RISK; REGULATORY T LYMPHOCYTE; THIRD TRIMESTER PREGNANCY;

ADULT; ANTIGENS, CD56; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-4; KILLER CELLS, NATURAL; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES; RECEPTORS, IGG; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS;

EID: 37849032623     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03555.x     Document Type: Article

References (43)

1. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy Multiple Sclerosis Group. N Engl J Med 1998 339 : 285 91.
2. Spector TD, Da Silva JA. Pregnancy and rheumatoid arthritis: an overview. Am J Reprod Immunol 1992 28 : 222 5.
3. Rabiah PK, Vitale AT. Noninfectious uveitis and pregnancy. Am J Ophthalmol 2003 136 : 91 8.
4. Muller AF, Berghout A. Consequences of autoimmune thyroiditis before, during and after pregnancy. Minerva Endocrinol 2003 28 : 247 54.
5. Chaouat G, Ledee-Bataille N, Dubanchet S, Zourbas S, Sandra O, Martal J. Reproductive immunology 2003: reassessing the Th1/Th2 paradigm? Immunol Lett 2004 92 : 207 14.
6. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005 308 : 1592 4.
7. Luppi P. How immune mechanisms are affected by pregnancy. Vaccine 2003 21 : 3352 7.
8. Irony-Tur-Sinai M, Grigoriadis N, Lourbopoulos A, Pinto-Maaravi F, Abramsky O, Brenner T. Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. Exp Neurol 2006 198 : 136 44.
9. Clark DA. Tolerance signaling molecules. Chem Immunol Allergy 2005 89 : 36 48.
10. Bebo BF Jr, Dveksler GS. Evidence that pregnancy specific glycoproteins regulate T-cell function and inflammatory autoimmune disease during pregnancy. Curr Drug Targets Inflamm Allergy 2005 4 : 231 7.
11. Sicotte NL, Liva SM, Klutch R et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002 52 : 421 8.
12. Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology 1999 52 : 1230 8.
13. Polanczyk MJ, Jones RE, Subramanian S et al. T lymphocytes do not directly mediate the protective effect of estrogen on experimental autoimmune encephalomyelitis. Am J Pathol 2004 165 : 2069 77.
14. Gilmore W, Arias M, Stroud N, Stek A, McCarthy KA, Correale J. Preliminary studies of cytokine secretion patterns associated with pregnancy in MS patients. J Neurol Sci 2004 224 : 69 76.
15. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993 14 : 353 6.
16. Sanchez-Ramon S, Navarro AJ, Aristimuno C et al. Pregnancy-induced expansion of regulatory T-lymphocytes may mediate protection to multiple sclerosis activity. Immunol Lett 2005 96 : 195 201.
17. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 2004 112 : 38 43.
18. Kruse N, Greif M, Moriabadi NF, Marx L, Toyka KV, Rieckmann P. Variations in cytokine mRNA expression during normal human pregnancy. Clin Exp Immunol 2000 119 : 317 22.
19. Marzi M, Vigano A, Trabattoni D et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996 106 : 127 33.
20. Saito S, Sakai M, Sasaki Y, Tanebe K, Tsuda H, Michimata T. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1 : Th2 cell ratio during normal human pregnancy and preeclampsia. Clin Exp Immunol 1999 117 : 550 5.
21. Reinhard G, Noll A, Schlebusch H, Mallmann P, Ruecker AV. Shifts in the TH1/TH2 balance during human pregnancy correlate with apoptotic changes. Biochem Biophys Res Commun 1998 245 : 933 8.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33 : 1444 52.
23. Airas L, Salmi M, Jalkanen S. Lymphocyte-vascular adhesion protein-2 is a novel 70-kDa molecule involved in lymphocyte adhesion to vascular endothelium. J Immunol 1993 151 : 4228 38.
24. Bielekova B, Catalfamo M, Reichert-Scrivner S et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006 103 : 5941 6.
25. Bielekova B, Richert N, Howard T et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004 101 : 8705 8.
26. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007 69 : 785 9.
27. Perini P, Wadhwa M, Buttarello M et al. Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients. J Neuroimmunol 2000 105 : 91 5.
28. Saraste M, Irjala H, Airas L. Expansion of CD56bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007 28 : 121 6.
29. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001 22 : 633 40.
30. Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG. The natural killer cell - friend or foe in autoimmune disease? Scand J Immunol 2002 55 : 432 41.
31. Kastrukoff LF, Lau A, Wee R, Zecchini D, White R, Paty DW. Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J Neuroimmunol 2003 145 : 103 14.
32. Infante-Duarte C, Weber A, Kratzschmar J et al. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J 2005 19 : 1902 4.
33. Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004 127 : 1917 27.
34. Trivedi PP, Roberts PC, Wolf NA, Swanborg RH. NK cells inhibit T cell proliferation via p21-mediated cell cycle arrest. J Immunol 2005 174 : 4590 7.
35. Huang D, Shi FD, Jung S et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006 20 : 896 905.
36. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 1997 186 : 1677 87.
37. Matsumoto Y, Kohyama K, Aikawa Y et al. Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis. Eur J Immunol 1998 28 : 1681 8.
38. Xu W, Fazekas G, Hara H, Tabira T. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005 163 : 24 30.
39. Vosshenrich CA, Garcia-Ojeda ME, Samson-Villeger SI et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 2006 7 : 1217 24.
40. Lundmark F, Duvefelt K, Iacobaeus E et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007 39 : 1108 13.
41. International Multiple Sclerosis Genetic Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007 357 : 851 62.
42. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004 199 : 971 9.
43. Feger U, Luther C, Poeschel S, Melms A, Tolosa E, Wiendl H. Increased frequency of CD4+CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 2007 147 : 412 8.